Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
With the election behind us, many are wondering what the next four years look like for the US economy. Drew Pettit, from Citi Group joins Cheddar to discuss.
Jeff Ostrowski, Mortgage & Housing Analyst at Bankrate, discusses mortgage rates in America and how the housing market will change under a second Trump term.
The NAACP has entered the VC space with a new fund that will invest in startups and fund managers that are focused on closing gaps facing communities of color.
Can a layoff lead to your next big thing? Issie Lapowsky, contributor for Inc. Magazine and Alphonzo Terrell, co-founder and CEO of Spill join us to discuss.
Meet Scorpion, the latest, Nvidia-powered service robot from Richtech Robotics which crafts personalized cocktails and wine selections based on your mood
Gina Heeb, finance reporter at The Wall Street Journal, joins us to discuss the current state of the real estate market and when things may turn around. Watch!
